SCA
TVTX icon

Snowden Capital Advisors’s Travere Therapeutics TVTX Stock Holding History

Snowden Capital Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$348K Sell
6,134
-725
-11% -$32.1K 0.01% 1007
2026
Q1 		$204K Sell
6,859
-335
-5% -$10K 0.01% 1216
2025
Q4 		$275K Buy
+7,194
New +$234K 0.01% 1077

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Snowden Capital Advisors's TVTX Position: Q2 2026 in Review

Snowden Capital Advisors reduced its Travere Therapeutics (TVTX) stake by 11% in Q2 2026, selling an estimated $32.1K and leaving 6,134 shares worth $348K. The position accounts for 0.01% of the portfolio, ranked #1007.

Snowden Capital Advisors first reported a position in TVTX in Q4 2025 and has held it in 3 quarters since. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Snowden Capital Advisors held 6,134 shares of Travere Therapeutics worth $348K as of Q2 2026.
  • Snowden Capital Advisors sold 725 Travere Therapeutics shares in Q2 2026, an estimated $32.1K.
  • Travere Therapeutics made up 0.01% of Snowden Capital Advisors's portfolio in Q2 2026, its #1007 holding.
  • Snowden Capital Advisors first reported a position in Travere Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Snowden Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.